Patient Filed Lawsuit Over Failed Heart Valve
A federal court is reviewing a claim after a heart valve failed years before its expected lifespan.
Updated on Oct. 14, 2026 in Heart Disease
Live Poll
Do you trust that medical device manufacturers are held sufficiently accountable for long-term product failures?
On August 18, 2026, Mark Lynch filed a product liability lawsuit against Abbott Laboratories regarding the failure of a Trifecta GT heart valve. The device failed eight years after implantation, prompting renewed scrutiny of the product line.
Why it matters
This litigation follows the July 2023 market removal of all Trifecta heart valves due to concerns about premature structural valve deterioration. Patients who received these devices face ongoing questions regarding their long-term health and the durability of their implants.
Between 2011 and 2023, the FDA received approximately 3,000 adverse event reports linked to the Trifecta heart valve series, which resulted in nearly 200 deaths. The reports highlight significant failures in devices that were marketed to last 15 to 20 years.
The players
Abbott Laboratories
A global medical device company that develops and manufactures cardiac technologies and heart valve replacements.
Mark Lynch
A patient who filed a product liability lawsuit following the failure of a surgically implanted heart valve.
The details
The Trifecta heart valve was designed with three flexible leaflets constructed from cow heart tissue and mounted onto a stent. These leaflets were intended to function like natural heart valves, but reports of structural deterioration indicated the tissue could break down prematurely. Abbott Laboratories, which acquired the product line from St. Jude Medical in 2017, ultimately removed the devices from the market to address these safety concerns.
Timeline
2011: St. Jude Medical marketed the original Trifecta heart valve.
2017: Abbott Laboratories acquired the Trifecta heart valve product line.
July 2023: Abbott Laboratories removed Trifecta heart valves from the market.
August 18, 2026: Mark Lynch filed a lawsuit in California Superior Court.
October 7, 2026: Lawsuit was removed to U.S. District Court.
Health Landscape
This case sits within the broader history of cardiac implant regulation and the subsequent removal of the Trifecta line from the market. It highlights the ongoing clinical challenge of monitoring the long-term durability of tissue-based heart valves.
If you or a family member received a heart valve implant, it is important to verify the make and model of the device with your cardiologist. Discuss any concerns about valve durability or potential symptoms—such as shortness of breath or unusual fatigue—with your physician.
The takeaway
The primary takeaway for patients is the importance of maintaining regular follow-up appointments to monitor the status of any cardiac implant. If you believe your health may be affected by a device recall, reach out to your surgeon or primary cardiologist for a clinical review of your records.
Further reading
For more information on managing conditions related to implants, visit our Heart Disease section.
Source note: This article includes information reported by AboutLawsuits.
Live Poll
Do you trust that medical device manufacturers are held sufficiently accountable for long-term product failures?
